is tirzepatide compound being discontinued Compounded (GLP-1/GIP) A Major GLP-1 Drug Shortage

The article notes discontinuation due to side effects typically runs 2 to 6 percent across agents, a much smaller figure than the reported incidence of nausea and gastrointestinal upset

Seven additional Phase 3 trials are expected to complete in 2026

Tirzepatide, a medication developed by Eli Lilly and Company, has shown promising results in the treatment of obesity and chronic weight management

Semaglutide has also been studied for cardiovascular benefit in certain patients with type 2 diabetes and established cardiovascular disease

Causes / Predisposing Factors Based on Virchows Triad (three major mechanisms that promote clot formation): 1